Twist Bioscience (TWST) Gross Margin (2017 - 2026)

Twist Bioscience has disclosed Gross Margin across 10 years of filings, most recently posting 51.59% for Q1 2026.

• In Q1 2026, Gross Margin rose 199.0% year-over-year to 51.59%; the TTM figure through Mar 2026 stood at 52.07% (up 537.0% YoY), while the FY2025 annual figure was 50.72%, up 811.0% from the prior year.
• Gross Margin slipped to 51.59% in Q1 2026, from 52.05% in the prior quarter.
• Over the last five years, Gross Margin for TWST reached as high as 53.4% in Q2 2025 and fell as low as 30.76% in Q1 2023.
• The 5-year median for Gross Margin is 44.88% (2022), against an average of 44.21%.
• Annual changes were most pronounced in 2023 — Gross Margin slumped 1045 bps — and 2024, when it surged 1025 bps.
• A 5-year view of Gross Margin shows it stood at 45.72% in 2022, then fell by 11 bps to 40.51% in 2023, then grew by 19 bps to 48.29% in 2024, then grew by 8 bps to 52.05% in 2025, then slipped by 1 bps to 51.59% in 2026.
• According to Business Quant data, Gross Margin over the past three periods registered 51.59%, 52.05%, and 51.35% for Q1 2026, Q4 2025, and Q3 2025 respectively.